Drugs for Lung Oat Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 149)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
BCG vaccine |
Approved, Investigational |
Phase 3 |
|
|
|
Synonyms:
BACILLUS CALMETTE GUERIN VACCINE
BACILLUS CALMETTE GUÉRIN VACCINE
Bacillus Calmette–Guérin (BCG) vaccine
|
Bacillus calmette-guerin live antigen, unspecified substrain
BCG
BCG vaccine
|
|
2 |
|
Atezolizumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
3 |
|
Memantine |
Approved, Investigational |
Phase 3 |
|
41100-52-1, 19982-08-2 |
4054 |
Synonyms:
1,3-Dimethyl-5-adamantanamine
1,3-Dimethyl-5-aminoadamantane
1,3-DIMETHYLAMINOADAMANTANE
1-Amino-3,5-dimethyladamantane
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
AKATINOL
Axura
Axura®|Ebixa®|Namenda®
D-145
DMAA
DRG-0267
Ebixa
Exiba
FP-01
Lundbeck brand OF memantine hydrochloride
|
MARIXINO
Memantin
Memantina
Memantina [INN-Spanish]
MEMANTINE
Memantine [INN]
MEMANTINE HCL
Memantine hydrochloride
Memantinum
Memantinum [INN-Latin]
Merz brand OF memantine hydrochloride
Namenda
NAMENDA XR
NEMDATINE
NSC-102290
SUN-Y7017
VALIOS
|
|
4 |
|
Dopamine |
Approved |
Phase 3 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
5 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
6 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
7 |
|
Etoposide |
Approved |
Phase 3 |
|
33419-42-0 |
36462 |
Synonyms:
(-)-Etoposide
(−)-ETOPOSIDE
(-)-etoposide|Etopophos®|Toposar®|trans-etoposide|VePesid®|VP 16-213|VP-16
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
alpha-D-Glucopyranosyl isomer etoposide
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
Celltop
Demethyl epipodophyllotoxin ethylidine glucoside
Eposide
Eposin
Eto gry
Eto-gry
Etomedac
Etopophos
Etopos
ETOPOSIDE
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
|
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
Lastet
Lemery brand OF etoposide
Medac brand OF etoposide
Novartis brand OF etoposide
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Riboposid
Ribosepharm brand OF etoposide
Sanfer brand OF etoposide
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
Vepesid
Vepesid J
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16-213
VP-16
VP-16-213
Zuyeyidal
|
|
8 |
|
Belotecan |
Investigational |
Phase 3 |
|
256411-32-2 |
9824190 |
Synonyms:
|
9 |
|
Vaccines |
|
Phase 3 |
|
|
|
10 |
|
Epoetin Alfa |
|
Phase 3 |
|
|
|
Synonyms:
BINOCRIT
EPO
EPOETIN ALFA
EPOGEN
|
EPREX
ERYTHROPOIETIN PRECURSOR
PROCRIT
|
|
11 |
|
Hematinics |
|
Phase 3 |
|
|
|
12 |
|
Immunologic Factors |
|
Phase 2, Phase 3 |
|
|
|
13 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
14 |
|
Dopamine Agents |
|
Phase 3 |
|
|
|
15 |
|
Antiparkinson Agents |
|
Phase 3 |
|
|
|
16 |
|
Excitatory Amino Acid Antagonists |
|
Phase 3 |
|
|
|
17 |
|
Etoposide phosphate |
|
Phase 3 |
|
|
16760419 |
Synonyms:
{4-[16-({7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-D][1,3]dioxin-6-yl}oxy)-12-oxo-4,6,13-trioxatetracyclo[7.7.0.0,.0,]hexadeca-1,3(7),8-trien-10-yl]-2,6-dimethoxyphenoxy}phosphonate
BMY-40481
ETOPOPHOS
ETOPOPHOS PRESERVATIVE FREE
|
ETOPOSIDE PHOSPHATE
Etoposide phosphoric acid
VP16
VP-16
|
|
18 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
19 |
|
Somatostatin |
Approved, Investigational |
Phase 1, Phase 2 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
20 |
|
Arsenic trioxide |
Approved, Investigational |
Phase 2 |
|
1327-53-3 |
518740 |
Synonyms:
Acide Arsenieux
Acide Arsenieux [French]
Anhydride Arsenieux
Anhydride Arsenieux [French]
Arseni trioxydum
Arsenic Blanc
Arsenic Blanc [French]
Arsenic Oxide
Arsenic oxidearsenous trioxide
Arsenic Sesquioxide
ARSENIC TRIOXIDE
Arsenic Trioxide [UN1561] [Poison]
Arsenic(III) oxide
Arsenic, White
arsénico trióxido
Arsenicum Album
Arsenigen Saure
Arsenigen Saure [German]
Arsenious acid
Arsenious Acid Anhydride
Arsenious Oxide
Arsenious trioxide
Arsenite
|
Arsenolite
Arsenous Acid
Arsenous Acid Anhydride
Arsenous anhydride
Arsenous Oxide
Arsenous Oxide Anhydride
Arsentrioxide
Arsodent
Claudelite
Claudetite
Crude Arsenic
Diarsenic oxide
Diarsenic trioxide
Di-Arsenic Trioxide
Diarsonic Trioxide
HSDB 419
Naonobin
Oxyde Arsenieux [ISO-French]
Poison Flour
TRISENOX
Trixenox
White Arsenic
|
|
21 |
|
Vinorelbine |
Approved, Investigational |
Phase 2 |
|
71486-22-1 |
44424639 60780 |
Synonyms:
5' Nor anhydrovinblastine
5'-Noranhydrovinblastine
5'-Nor-anhydrovinblastine
Navelbine
Navelbine Base
Vinorelbin
Vinorelbina
Vinorelbina [Spanish]
|
Vinorelbine
VINORELBINE BASE
Vinorelbine bitartrate
Vinorelbine ditartarate
Vinorelbine ditartrate
Vinorelbine tartrate
Vinorelbinum
Vinorelbinum [Latin]
|
|
22 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
23 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
24 |
|
Temozolomide |
Approved, Investigational |
Phase 1, Phase 2 |
|
85622-93-1 |
5394 |
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
BRN 5547136
CCRG 81045
CCRG-81045
CCRIS 8996
m & b 39831
m And b 39831
m And b39831
m And b-39831
M&B 39831
M&B-39831
M-39831
MB 39831
Methazolastone
NSC 362856
NSC-362856
|
SCH 52365
SCH-52365
Temodal
Temodar
TEMOMEDAC
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Témozolomide
Temozolomide hexyl ester
Temozolomidum
Temozolomidum [Latin]
TMZ
TMZ Bioshuttle
TMZA-he
TMZ-Bioshuttle
|
|
25 |
|
Irinotecan |
Approved, Investigational |
Phase 1, Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
26 |
|
Lamivudine |
Approved, Investigational |
Phase 2 |
|
134678-17-4 |
60825 |
Synonyms:
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-2'-Deoxy-3'-thiacytidine
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
3TC
3'-Thia-2',3'-dideoxycytidine
BCH 189
BCH 189, (-)-
BCH-189
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
b-L-2',3'-Dideoxy-3'-thiacytidine
b-L-3'-Thia-2',3'-dideoxycytidine
Epivir
|
EPIVIR-HBV
Epzicom
GR-109714X
Hepitec
HEPTOVIR
LAMIVUDIN
LAMIVUDINA
LAMIVUDINE
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-isomer
LAMIVUDINUM
ZEFFIX
Î’-L-2',3'-dideoxy-3'-thiacytidine
Î’-L-3'-thia-2',3'-dideoxycytidine
|
|
27 |
|
Rucaparib |
Approved, Investigational |
Phase 1, Phase 2 |
|
283173-50-2 |
9931954 |
Synonyms:
AG014699
AG-014699
AG-014699|AG014699|AG14447|PF-01367338|Rubraca®
AG14447
AG-14447
|
AG-14447ag-014699Rucaparib
PF-01367338
Rubraca
RUCAPARIB
Rucaparibum
|
|
28 |
|
Niraparib |
Approved, Investigational |
Phase 1, Phase 2 |
|
1038915-60-4 |
24958200 |
Synonyms:
COMPOUND 56 [PMID 19873981]
compound 56 [PMID 19873981]|MK 4827|MK-4827|Zejula®
JNJ-64091742
MK 4827
|
MK4827
MK-4827
NIRAPARIB
ZL-2306
|
|
29 |
|
Erlotinib |
Approved, Investigational |
Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
30 |
|
Lapatinib |
Approved, Investigational |
Phase 2 |
|
231277-92-2, 388082-78-8 |
208908 |
Synonyms:
FMM
FMM|GW 572016|GW572016|Tykerb®|Tyverb®
GSK-572016
GW 572016
GW-2016
GW572016
GW-572016
GW572016F
GW-572016F
GW-572016X
LAP016
LAPATINIB
LAPATINIB DITOLUENESULFONATE MONOHYDRATE
|
Lapatinib ditosylate
LAPATINIB DITOSYLATE MONOHYDRATE
Lapatinib tosilate hydrate
N-(3-Chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURANYL]-4-QUINAZOLINAMINE
Tycerb
Tykerb
TYVERB
|
|
31 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
32 |
|
Talazoparib |
Approved, Investigational |
Phase 2 |
|
1207456-01-6 |
135565082 |
Synonyms:
BMN 673
BMN-673
BMN-673|BMN673|Talzenna®
|
LT-673
TALAZOPARIB
Talzenna
|
|
33 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
34 |
|
Prednisone |
Approved, Vet_approved |
Phase 2 |
|
53-03-2 |
5865 |
Synonyms:
1,2-Dehydrocortisone
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
Acis brand OF prednisone
Acsis, prednison
Adasone
Ancortone
Apo-prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
Cutason
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta-cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Deltacortone
Delta-cortone
DELTA-DOME
Deltasone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
FERNISONE
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
Hoechst brand OF prednisone
Hostacortin
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
|
Liquid pred
Lisacort
LODOTRA
Lodotra®|Sterapred®
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Mibe brand OF prednisone
Nisona
Nizon
Novoprednisone
NSC-10023
Nurison
Orasone
Origen Prednisone
Panafcort
Panasol
PARACORT
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
PREDN
Predni tablinen
PREDNICEN-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
PREDNISONE INTENSOL
PREDNISONE TABLETS
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Pronison
Pronisone
RAYOS
Rectodelt
Retrocortine
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
SERVISONE
Solvay brand OF prednisone
Sone
Sterapred
Supercortil
Trommsdorff brand OF prednisone
Ultracorten
Ultracortene
Winpred
Wojtab
Zenadrid
|
|
35 |
|
Methyltestosterone |
Approved |
Phase 2 |
|
58-18-4 |
6010 |
Synonyms:
17 alpha Methyltestosterone
17 beta Hydroxy 17 methyl 4 androsten 3 one
17 beta Methyltestosterone
17 beta-Hydroxy-17-methyl-4-androsten-3-one
17 beta-Methyltestosterone
17 Epimethyltestosterone
17(a)-Methyl-delta(4)-androsten-17(b)-ol-3-one
17(a)-Methyl-δ(4)-androsten-17(b)-ol-3-one
17(alpha)-Methyl-Delta(4)-androsten-17(beta)-ol-3-one
17(Α)-methyl-δ(4)-androsten-17(β)-ol-3-one
17alpha Methyl testosterone
17alpha Methyltestosterone
17alpha-Methyl-3-oxo-4-androsten-17beta-ol
17alpha-Methyl-Delta(4)-androsten-17beta-ol-3-one
17alpha-Methyl-delta-androsten-17beta-ol-3-one
17alpha-Methyltestosterone
17alpha-Methyl-testosterone
17-alpha-Methyltestosterone
17a-Methyl-3-oxo-4-androsten-17b-ol
17a-Methyl-delta(4)-androsten-17b-ol-3-one
17a-Methyltestosterone
17a-Methyl-δ(4)-androsten-17b-ol-3-one
17beta Hydroxy 17 methyl 4 androsten 3 one
17beta Methyltestosterone
17beta-Hydroxy-17-methyl-4-androsten-3-one
17beta-Hydroxy-17-methylandrost-4-en-3-one
17-beta-Hydroxy-17-methylandrost-4-en-3-one
17beta-Methyltestosterone
17b-Hydroxy-17-methylandrost-4-en-3-one
17-b-Hydroxy-17-methylandrost-4-en-3-one
17-Epimethyltestosterone
17-Methyltestosterone
17Α-methyl-3-oxo-4-androsten-17β-ol
17Α-methyltestosterone
17Α-methyl-δ(4)-androsten-17β-ol-3-one
17Α-METHYL-Δ4-ANDROSTEN-17Β-OL-3-ONE
17Î’-hydroxy-17-methylandrost-4-en-3-one
17-Î’-hydroxy-17-methylandrost-4-en-3-one
4-Androstene-17alpha-methyl-17beta-ol-3-one
4-Androstene-17a-methyl-17b-ol-3-one
|
4-Androstene-17α-methyl-17β-ol-3-one
Android
Android (methyltestoterone)
Android 10
Android 25
Android 5
Android-10
Android-25
Android-5
CDB-110
Global pharmaceutical brand OF methyltestosterone
ICN brand 1 OF methyltestosterone
ICN brand 2 OF methyltestosterone
L 589.372
L-589.372
L-589372
Mesteron
Mesterone
Metandren
Methitest
Methyltestosterone
METHYLTESTOSTERONE CIII
Methyltestosteronum
Metiltestosterona
NSC-139965
NSC-9701
Oreton
ORETON METHYL
PERANDREN
PLEX HORMONE
POTENSAN FTE
RU 24400
RU-24400
Schering brand OF methyltestosterone
Star brand OF methyltestosterone
Testoviron
TESTOVIS
Testred
U-2842
Virilon
|
|
36 |
|
Testosterone undecanoate |
Approved, Investigational |
Phase 2 |
|
5949-44-0 |
21873174 65157 |
Synonyms:
2,15-Dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl undecanoic acid
ANDRIOL
AVEED
JATENZO
MK-3033
NEBIDO
ORG-538
RESTANDOL
|
RESTANDOL TESTOCAP
Testosterone undecanoate
Testosterone undecanoic acid
Testosterone undeconate
Testosterone undecylate
TSX-011
UNDESTOR
|
|
37 |
|
Testosterone enanthate |
Approved |
Phase 2 |
|
315-37-7 |
9416 |
Synonyms:
17-((1-Oxoheptyl)oxy)androst-4-en-3-one
17beta-Enanthoxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-en-3-one enanthate
17beta-Hydroxyandrost-4-en-3-one heptanoate
17beta-Hydroxyandrost-4-en-3-one heptanoic acid
17b-Hydroxyandrost-4-en-3-one heptanoate
17b-Hydroxyandrost-4-en-3-one heptanoic acid
17-Hydroxyandrost-4-en-3-one, 17-heptanoate
17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid
17Î’-hydroxyandrost-4-en-3-one heptanoate
17Î’-hydroxyandrost-4-en-3-one heptanoic acid
4-Androsten-17beta-ol-3-one 17-enanthate
4-Androsten-3-one 17beta-enanthate
Androgyn l.a.
Andropository
Androtardyl
Atlatest
BTG Brand OF testosterone enanthate
DEA no. 4000
Delatest
Delatestryl
DePatestrye
depo-testro Med
Ditate
Durathate
eifelfango Brand OF testosterone enanthate
Everone
Exten test
Jenapharm brand OF testosterone enanthate
Malogen l.a.
Malogen l.a.200
NSC-17591
Orquisteron-e
Pasadena brand OF testosterone enanthate
Primoteston depot
|
Primotestone
reposo TMD
Roberts brand OF testosterone enanthate
Rotexmedica brand OF testosterone enanthate
Rugby brand OF testosterone enanthate
Schering brand OF testosterone enanthate
Testanthate
Testate
Testenate
Testinon
Testoenant
Testonenant
Testosteron depot-rotexmedica
Testosteron-depot eifelfango
Testosteron-depot jenapharm
Testosterone 17beta-heptanoate
Testosterone 17beta-heptanoic acid
Testosterone 17-enanthate
Testosterone 17-enanthic acid
Testosterone enantate
Testosterone enanthate
TESTOSTERONE ENANTHATE CIII
Testosterone enanthic acid
Testosterone heptanoate
Testosterone heptanoic acid
Testosterone heptoate
Testosterone heptoic acid
Testosterone heptylate
Testosterone oenanthate
Testostroval
Testrin p.a.
Theramed brand OF testosterone enanthate
Theramex
XYOSTED (AUTOINJECTOR)
|
|
38 |
|
Testosterone |
Approved, Investigational |
Phase 2 |
|
58-22-0 |
5408 6013 |
Synonyms:
(+-)-8-ISO-TESTOSTERONE
(+-)-RETROTESTOSTERONE
(+)-TESTOSTERONE
(+-)-TESTOSTERONE
(17B)-17-HYDROXY-ANDROST-4-EN-3-ONE
(1S,2R,10R,11S,14S,15S)-14-HYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
13-ISO-TESTOSTERONE
17 beta Hydroxy 4 androsten 3 one
17 beta Hydroxy 8 alpha 4 androsten 3 one
17A-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17A-HYDROXY-13A-ANDROST-4-EN-3-ONE
17A-HYDROXY-14B-ANDROST-4-EN-3-ONE
17A-HYDROXY-ANDROST-4-EN-3-ONE
17-beta-Hydroxy-4-androsten-3-one
17BETA-HYDROXY-4-ANDROSTEN-3-ONE
17-beta-Hydroxy-8 alpha-4-androsten-3-one
17B-HYDROXY-(10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-13A-ANDROST-4-EN-3-ONE
17b-Hydroxy-4-androsten-3-one
17B-HYDROXY-8A-ANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ON
17B-HYDROXYANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ONE
17B-HYDROXYANDROST-4-ENE-3-ONE
17B-HYDROXY-D4-ANDROSTEN-3-ONE
17B-TESTOSTERONE
17-HYDROXY-10,13-DIMETHYL-1,2,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
17-HYDROXY-ANDROST-4-EN-3-ONE
17-HYDROXY-D4-ANDROSTEN-3-ONE
17Î’-hydroxy-4-androsten-3-one
4-ANDROSTEN-17BETA-OL-3-ONE
4-Androsten-17b-ol-3-one
4-ANDROSTEN-17Î’-OL-3-ONE
4-ANDROSTEN-3-ONE-17B-OL
8 Isotestosterone
8-Isotestosterone
8-ISO-TESTOSTERONE
9B,10A-TESTOSTERONE
9B-TESTOSTERONE
Andriol
Andro
Andro 100
Andro L.A. 200
ANDRODERM
Androderm®|Delatestryl®
ANDROGEL
ANDROGEL 1%
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
ANDROPATCH
Andropository 200
Androsorb
ANDROST-4-EN-17B-OL-3-ONE
ANDROST-4-ENE-17B-OL-3-ONE
Androtop
Andrusol
Andryl 200
AstraZeneca brand OF testosterone
Auxilium pharmaceuticals inc. brand OF testosterone
AXIRON
Bartor brand OF testosterone
Beta Testosterone
Bio-T-Gel
CDB 111C
CEPA brand OF testosterone
Cristerona T
Cristerone T
D4-ANDROSTEN-17B-OL-3-ONE
Dea No. 4000
Delatest
DELATESTRYL
Depotest
Depo-Testosterone
Depo-Testosterone Cypionate
Dr. kade brand OF testosterone
Epitestosteron
Everone 200
Faulding brand OF testosterone
Ferring brand OF testosterone
FORTESTA
Geno-cristaux gremy
GlaxoSmithKline brand OF testosterone
Hauck brand OF testosterone
Histerone
Homosteron
Homosterone
INTRINSA
Libigel
LUMITESTOSTERON
|
Malerone
Malestrone
Malogen in Oil
Malogen, Aquaspension Injection
MERTESTATE
Metandren
Methyltestosterone
NATESTO
Neo-Hombreol F
Neotestis
Neo-Testis
NSC-9700
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Ortho brand OF testosterone
Paladin brand OF testosterone
Pasadena brand OF testosterone
Perandren
Percutacrine androgenique
Primotest
Primoteston
RAC-17B-HYDROXY-(13A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(9B,10A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-ANDROST-4-EN-3-ONE
Relibra
RETROTESTOSTERONE
Scheinpharm Testone-Cyp
Schering brand OF testosterone
SmithKline beecham brand OF testosterone
Solvay brand OF testosterone
Sterotate
STRIANT
STRIANT SR
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
TESTIM
TESTIM 1%
Testobase
TESTODERM
TESTODERM TTS
TESTOGEL
Testoject-50
Testolent
Testolin
TESTOPATCH
TESTOPEL
Testopel Pellets
Testopropon
TESTORAL
Testosteroid
TESTOSTERON
TESTOSTERONA
Testosterona [INN-Spanish]
TESTOSTERONE
TESTOSTÉRONE
TESTOSTERONE CIII
Testosterone Cypionate
Testosterone Enanthate
Testosterone Hydrate
Testosterone sulfate
TESTOSTERONUM
Testosteronum [INN-Latin]
Testostosterone
Testoviron
Testoviron schering
Testoviron T
Testred
Testred Cypionate 200
Testrin-P.A
Testro aq
TESTRONE
Testryl
TOSTRAN
Tostrelle
Tostrex
Trans-Testosterone
Ulmer brand OF testosterone
Unimed brand OF testosterone
Viatrel
Virilon
Virilon IM
Virormone
VIROSTERONE
VOGELXO
Watson brand OF testosterone
|
|
39 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
40 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
41 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
42 |
|
Topotecan |
Approved, Investigational |
Phase 2 |
|
123948-87-8, 119413-54-6 |
60699 60700 |
Synonyms:
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(Dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
Hycamptamine
HYCAMPTIN
Hycamtamine
Hycamtin
Hydrochloride, nogitecan
Hydrochloride, topotecan
Nogitecan hydrochloride
NSC-609699
Potactasol
SK And F 104864 a
SK And F104864a
SK And F-104864-a
|
SK&F-S-104864A
SKF-104864
SK-S-104864-A
SmithKline beecham brand OF topotecan hydrochloride
Topotecan
TOPOTECAN HCL
Topotecan hydrochloride
Topotecan lactone
Topotecan monohydrochloride, (S)-isomer
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
|
|
43 |
|
Pomalidomide |
Approved |
Phase 1, Phase 2 |
|
19171-19-8 |
134780 |
Synonyms:
3-aminio-phthalimido-Glutarimide
3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide
3-Aminophthalimidoglutarimide
4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione
4-Aminothalidomide
CC 4047
CC-4047
CC-4047|IMID-3|Imnovid®|Pomalyst®
|
IMID-3
IMNOVID
Pomalidomida
POMALIDOMIDE
Pomalyst
S-3-amino-phthalimido-Glutarimide
S-3APG
|
|
44 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 1, Phase 2 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
45 |
|
Pemetrexed |
Approved, Investigational |
Phase 1, Phase 2 |
|
150399-23-8, 137281-23-3 |
60843 446556 135565230 |
Synonyms:
(2R)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate
ALIMTA
Alimta®|LY-231514
Disodium, pemetrexed
LY-2315
LY231514
|
LY-231514
MTA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-D)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NSC-698037
Pemetrexed
Pemetrexed disodium
|
|
46 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
47 |
|
Bemiparin |
Approved, Investigational |
Phase 2 |
|
91449-79-5 |
|
Synonyms:
|
48 |
|
Zoledronic acid |
Approved |
Phase 2 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
ácido zoledrónico
ACLASTA
Aclasta®|CGP-42446|CGP-42446A|Reclast®|zoledronate|Zometa®
ANHYDROUS ZOLEDRONIC ACID
CGP-42446
CGP-42446A
Novartis brand OF zoledronic acid
|
Reclast
ZERLINDA
ZOL
ZOL446
ZOLEDRONATE
Zoledronic acid
Zoledronic acid anhydrous
ZOLEDRONIC ACID HYDRATE
ZOLEDRONIC ACID MONOHYDRATE
ZOLEDRONIC ACID, ANHYDROUS
Zometa
Zometa Concentrate
|
|
49 |
|
Picropodophyllin |
Approved, Investigational |
Phase 2 |
|
518-28-5, 477-47-4 |
10607 72435 |
Synonyms:
(−)-podophyllotoxin
(-)-Podophyllotoxin
6,7]NAPHTHO[2,3-D][1,3]DIOXOL-6(5AH)-ONE
9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDROFURO[3',4'
9-HYDROXY-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-D][1,3]dioxol-6(5ah)-one
Ardern brand OF podophyllotoxin
AXL-1717
AXL1717|podofilox
Canderm brand OF podophyllotoxin
Condyline
Condylox
CPH86
Epipodophyllotoxin
Fides ecopharma brand OF podophyllotoxin
Hamilton brand OF podophyllotoxin
Newport brand OF podophyllotoxin
NSC-24818
NSC-36407
Oclassen brand OF podophyllotoxin
Paddock brand OF podophyllotoxin
Paladin brand OF podophyllotoxin
|
PICROPODOPHYLLIN
PICROPODOPHYLLOTOXIN
PODOCON-25
Podofilm
Podofilox
Podophyllinate lactone
Podophyllinic acid lactone
Podophyllotoxin
Podophyllotoxin 7
PODOPHYLLOTOXIN PICROPODOPHYLLIN
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-isomer
PPT
Stiefel brand OF podophyllotoxin
Wartec
Warticon
Wolff brand OF podophyllotoxin
Yamanouchi brand OF podophyllotoxin
|
|
50 |
|
Olaparib |
Approved |
Phase 2 |
|
763113-22-0 |
23725625 |
Synonyms:
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
AZ2281
AZ-2281
AZD2281
AZD-2281
AZD-2281|AZD2281|Lynparza®
|
KEYLYNK-010 COMPONENT OLAPARIB
KU-0059436
KU59436
KU-59436
Lynparza
OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
|
|
Interventional clinical trials:
(show top 50)
(show all 139)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer |
Unknown status |
NCT02688036 |
Phase 3 |
|
2 |
A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer |
Completed |
NCT00826644 |
Phase 3 |
Belotecan;Etoposide;Cisplatin |
3 |
The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG |
Completed |
NCT00037713 |
Phase 3 |
|
4 |
A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy |
Completed |
NCT00270166 |
Phase 3 |
epoetin alfa |
5 |
Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) |
Recruiting |
NCT05058651 |
Phase 2, Phase 3 |
Carboplatin;Cisplatin;Etoposide |
6 |
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab |
Recruiting |
NCT03811002 |
Phase 2, Phase 3 |
Atezolizumab;Carboplatin;Cisplatin;Etoposide |
7 |
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) |
Recruiting |
NCT04155034 |
Phase 3 |
|
8 |
Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial |
Recruiting |
NCT04402788 |
Phase 2, Phase 3 |
Atezolizumab |
9 |
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer |
Recruiting |
NCT04804644 |
Phase 3 |
Memantine Hydrochloride |
10 |
REPLATINUM: A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer |
Active, not recruiting |
NCT05566041 |
Phase 3 |
RRx-001 + eLOOP Device;Cisplatin/carboplatin plus etoposide |
11 |
A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer |
Terminated |
NCT03699956 |
Phase 3 |
Cisplatin/carboplatin plus etoposide |
12 |
Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer |
Unknown status |
NCT01900951 |
Phase 2 |
Temozolomide |
13 |
Phase II Clinical Trial of Toripalimab (JS001), a Recombinant Humanized Anti-PD-1 Monoclonal PD1 Antibody, as Monotherapy for Patients With Small Cell Esophageal Carcinoma Who Failed Chemotherapy |
Unknown status |
NCT03811379 |
Phase 2 |
Toripalimab |
14 |
Phase â…¡ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer |
Unknown status |
NCT01635400 |
Phase 2 |
Irinotecan |
15 |
An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer |
Completed |
NCT00412880 |
Phase 2 |
BI 2536 |
16 |
A Phase I/II Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer |
Completed |
NCT00126828 |
Phase 1, Phase 2 |
|
17 |
Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer |
Completed |
NCT00191750 |
Phase 2 |
Pemetrexed |
18 |
Phase I/II Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-line Therapy in Chemotherapy-naïve Patients With Extensive-disease (ED) Stage Small-cell Lung Cancer (SCLC) |
Completed |
NCT00359359 |
Phase 1, Phase 2 |
Sagopilone (BAY86-5302, ZK 219477);Cisplatin |
19 |
Phase II Study of Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Patients With Limited Stage Small Cell Lung Cancer |
Completed |
NCT00308529 |
Phase 2 |
irinotecan;carboplatin;bevacizumab |
20 |
A Phase II Trial of Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer |
Completed |
NCT00305942 |
Phase 2 |
Topotecan;carboplatin |
21 |
Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC) |
Completed |
NCT00298896 |
Phase 2 |
SNS-595 |
22 |
A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer |
Completed |
NCT00294931 |
Phase 2 |
irinotecan;carboplatin;bevacizumab |
23 |
A Phase II Study Of Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer |
Completed |
NCT00294190 |
Phase 2 |
Topotecan |
24 |
A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer |
Completed |
NCT00284154 |
Phase 2 |
Vinflunine |
25 |
Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer |
Completed |
NCT00046787 |
Phase 2 |
OSI-211 (Liposomal Lurtotecan) |
26 |
A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung |
Completed |
NCT02936323 |
Phase 1, Phase 2 |
PEN-221 |
27 |
A Single Arm, Two-Stage Phase II Study of Arsenic Trioxide in Previously Treated Small Cell Lung Cancer |
Completed |
NCT01470248 |
Phase 2 |
Arsenic Trioxide |
28 |
Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study |
Completed |
NCT00453154 |
Phase 1, Phase 2 |
Carboplatin;Cisplatin;Etoposide;Sunitinib Malate |
29 |
Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage |
Completed |
NCT00416455 |
Phase 1, Phase 2 |
ferumoxtran-10 |
30 |
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer |
Completed |
NCT01642251 |
Phase 1, Phase 2 |
Cisplatin;Etoposide;Veliparib;Placebo |
31 |
Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer |
Completed |
NCT00217633 |
Phase 2 |
|
32 |
A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix |
Completed |
NCT00309959 |
Phase 2 |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation |
33 |
A Clinical Trial of Increased Chest Radiotherapy Dose for Limited Stage Small Cell Lung Cancer |
Completed |
NCT00907569 |
Phase 2 |
|
34 |
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) |
Completed |
NCT02489903 |
Phase 2 |
RRx-001;Cisplatin;Etoposide;Carboplatin;Irinotecan;Vinorelbine;Doxil;Gemcitabine;Taxane;Paclitaxel;Nab-Paclitaxel;Pemetrexed |
35 |
A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix |
Completed |
NCT01266447 |
Phase 2 |
Topotecan Hydrochloride;Veliparib |
36 |
PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX |
Completed |
NCT02164461 |
Phase 1, Phase 2 |
|
37 |
An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer |
Completed |
NCT01505868 |
Phase 1, Phase 2 |
Cabazitaxel;Carboplatin |
38 |
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
Recruiting |
NCT03333616 |
Phase 2 |
Ipilimumab;Nivolumab |
39 |
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers |
Recruiting |
NCT03554473 |
Phase 1, Phase 2 |
M7824;Topotecan;Temozolomide |
40 |
Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy |
Recruiting |
NCT00100256 |
Phase 1, Phase 2 |
Rhenium (Re 188 P2045, BAY86-5284) |
41 |
A Phase II Trial of Lamivudine in Combination With Chemoimmunotherapy in Patients With Extensive Stage SCLC |
Recruiting |
NCT04696575 |
Phase 2 |
Carboplatin;Etoposide;Lamivudine |
42 |
Phase II Clinical Trial of Durvalumab (MEDI4736) and Topotecan or Lurbinectedin in Patients With Relapsed Extensive Stage Small Cell Lung Cancer Previously Treated With Chemotherapy and Immunotherapy |
Recruiting |
NCT04607954 |
Phase 2 |
Lurbinectedin;Topotecan Hydrochloride |
43 |
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix |
Recruiting |
NCT05063916 |
Phase 2 |
AK104 |
44 |
Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers |
Recruiting |
NCT04209595 |
Phase 1, Phase 2 |
PLX038;Rucaparib |
45 |
A Study of Erdafitinib in Castration-Resistant Prostate Cancer Patients Evaluating Markers of Bone Remodeling and FGF Signaling in Plasma and Bone Marrow |
Recruiting |
NCT04754425 |
Phase 2 |
Erdafitinib |
46 |
A Phase I/II Trial of PARP Inhibition, Radiation, and Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PRIO Trial |
Recruiting |
NCT04728230 |
Phase 1, Phase 2 |
Carboplatin;Etoposide;Olaparib |
47 |
Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype |
Recruiting |
NCT03910660 |
Phase 1, Phase 2 |
BXCL701 plus Pembrolizumab;BXCL701 monotherapy |
48 |
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) |
Recruiting |
NCT03866382 |
Phase 2 |
Cabozantinib S-malate |
49 |
An Open-Label Phase 1b Dose-Finding Trial Evaluating the Safety of Niraparib and Temozolomide and Atezolizumab in Participants With Advanced Solid Tumors and Expansion to a Phase 2 Trial Comparing the Effects of Niraparib and Temozolomide Plus Atezolizumab vs. Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (TRIO-US L-06) |
Recruiting |
NCT03830918 |
Phase 1, Phase 2 |
Niraparib;Temozolomide |
50 |
Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC) |
Recruiting |
NCT04701307 |
Phase 2 |
Niraparib |
|